Background Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin
amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant …

The high rate of clinical response to protein-kinase-targeting drugs matched to cancer
patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) …

The development of selective inhibitors for discrete anti-apoptotic BCL-2 family proteins
implicated in pathologic cell survival remains a formidable but pressing challenge. Such …

Rodent models produce data which underpin biomedical research and non-clinical drug
trials, but translation from rodents into successful clinical outcomes is often lacking. There is a …

Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may
improve patient selection, response to therapy, and rational treatment designs. One approach …

Although next-generation sequencing has revolutionized the ability to associate variants with
human diseases, diagnostic rates and development of new therapies are still limited by a …

A promising approach to cancer therapy is to elicit apoptosis with “BH3 mimetic” drugs, which
target proteins of the BCL-2 family. As of yet, however, such drugs can target only certain …

Introduction: This study sought to estimate the global prevalence of transthyretin familial
amyloid polyneuropathy (ATTR‐FAP). Methods: Prevalence estimates and information …

In light of the number of studies conducted to examine the treatment of cognitive impairment
associated with schizophrenia (CIAS), we critically reviewed recent CIAS trials. Trials were …

People with psychiatric disabilities experience disproportionately high rates of unemployment.
As research evidence is mounting regarding effective vocational programs, interest is …